Your session is about to expire
← Back to Search
Nirmatrelvir + Ritonavir for COVID-19
This trial is testing a medication to see if it can help treat people with COVID-19 who are immunocompromised and may benefit from a longer treatment duration.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2011 Phase 4 trial • 25 Patients • NCT01232127
Find a Location
Who is running the clinical trial?
- Your immune system is not working properly.If you have any signs or symptoms of COVID-19 on the day of enrollment, you will not be able to participate.
- Group 1: Nirmatrelvir plus ritonavir for 15 days
- Group 2: Nirmatrelvir plus ritonavir for 10 days
- Group 3: Nirmatrelvir plus ritonavir for 5 days
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many areas within the state are conducting this research endeavor?
"From San Francisco to Vancouver, the trial encompasses 23 clinics; CRS Outpatient Services UCSF and the Winchester District Memorial Hospital are two notable examples."
What potential hazards come with taking Ritonavir?
"There is some evidence of safety found in Phase 2 data, so we have assigned Ritonavir a rating of 2."
Is this project currently open to participants?
"Correct. Clinicaltrials.gov has indicated that this trial is actively looking for participants; the original post was published on August 3rd 2022, with an update made on November 16th 2022."
What is the current enrollment number for this research endeavor?
"This clinical trial necessitates the participation of 200 qualified individuals. Locations enrolled in this program include CRS Outpatient Services UCSF in California and Vancouver Infectious Diseases Centre located in British Columbia."
Share this study with friends